Medline ® Abstract for Reference 11

3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are safe and effective in lowering low-density lipoprotein cholesterol. As a result, they confer an all-cause mortality benefit across a wide range of patient groups. The utility of statins is limited by their adverse effects, including myalgias and rhabdomyolysis. These clinical events, plus other symptoms, constitute what is termed statin myopathy. This review summarizes current concepts of statin myopathy and presents strategies to minimize statin-associated myopathic complaints.